Sunitinib or sorafenib for papillary kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how well sunitinib or sorafenib work as a first treatment for a type of kidney cancer called papillary renal cell carcinoma (PRCC) that cannot be removed with surgery or has spread. It aims to understand real-world results in Chinese patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have papillary kidney cancer (confirmed by biopsy or pathology) that is advanced or has spread, and cannot be removed with surgery
- You received sunitinib or sorafenib as your first cancer treatment for this condition
- You haven't had any other cancer in the past 5 years (except for non-melanoma skin cancer or cancer that was cured)
- You did not receive any other cancer treatments (like chemotherapy or immunotherapy) along with sunitinib or sorafenib
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether extra treatment after surgery can help people with a certain type of kidney cancer (stage III papillary kidney cancer) that is at high risk of coming back. The goal is to see if this approach improves outcomes.
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
This trial tests a first-line precision treatment for clear cell kidney cancer that has spread or cannot be removed. It aims to match the treatment to your cancer's protein profile to improve outcomes.
This study tests what happens when people with advanced kidney cancer switch their treatment after the first one stops working. It looks at two different switch options: going from a TKI to a TKI plus immunotherapy, or from a TKI plus immunotherapy back to a TKI.
This trial tests a combination of two drugs, RP2 (an oncolytic virus injected into tumors) and tivozanib (a daily pill), for people with advanced kidney cancer that has clear-cell or sarcomatoid features and has grown after prior immunotherapy and a targeted therapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs—bicalutamide and sunitinib—for people with advanced kidney cancer that no longer responds to TKI therapy. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Hear when a new Papillary Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.